Medication
Jamp Lisdexamfetamine
DIN 02535181 · Jamp Pharma Corporation Likely a generic
What it is
- Active ingredients
- Lisdexamfetamine Dimesylate — 70 mg
- Form and route
- Capsule · Oral
- Schedule
- CONTROLLED DRUGS (CDSA I)
- Authorised since
- 2025-07-17
Source: Health Canada — Drug Product Database. Data current as of 2026-08-12.
Products with the same active ingredient
- Vyvanse
- Teva-Lisdexamfetamine
- Sandoz Lisdexamfetamine Capsules
- Apo-Lisdexamfetamine Capsules
- Pro-Lisdexamfetamine
Grouped by Health Canada’s active-ingredient group number. Products in a group do not always share a strength — check the strength above against your own. Sharing an active ingredient does not mean two products can be substituted for each other: whether a substitution is permitted is a provincial decision, and this page does not show it. Ask a pharmacist.
Watch this medication
Ontario Drug Benefit coverage
As of 31 July 2026Off-formulary interchangeable Part III-B
Ontario has designated this product interchangeable with a brand product, but it is not an ODB benefit — Part III-B, Off-Formulary Interchangeable. Ontario does not pay for it under the benefit list.
Source: Ontario Ministry of Health — ODB Formulary. Data current as of 2026-07-28. Ontario only. Formulary edition 4342, effective 31 July 2026.
Products Ontario considers interchangeable
As of 31 July 2026Ontario groups these products together at 70mg Cap and will substitute one for another at a pharmacy counter in Ontario.
- Apo-Lisdexamfetamine Capsules 02546728Apotex Inc
- Sandoz Lisdexamfetamine Capsules 02546302Sandoz Canada Incorporated
- Teva-Lisdexamfetamine 02545942Teva Canada Limited
- Vyvanse 02458071Takeda Canada Inc
Ontario lists 1 further product in this group that is not currently marketed in Canada. It is not shown.
This is Ontario’s designation, under the Ontario Drug Benefit program, and it applies in Ontario. It is a different statement from the same-active-ingredient list above, which is Health Canada’s grouping and carries no substitution meaning at all. No other province’s rules are shown on this page, and a designation here is not a recommendation to switch — that is a conversation with a pharmacist or prescriber.
Source: Ontario Ministry of Health — ODB Formulary. Data current as of 2026-07-28. Ontario only. Formulary edition 4342, effective 31 July 2026.
How it is classified
- Anatomical main group
- Nervous system
- ATC code
- N06BA12
The Anatomical Therapeutic Chemical code records the body system a medicine acts on and its chemical grouping. It is not a statement of what this medication treats, and nothing on this page is. For the full classification of N06BA12, see the WHO ATC/DDD Index.
Recalls and safety alerts
As of 12 August 2026No Health Canada recall has been matched to this product.
This is not a statement that no recall exists for this medication. Health Canada’s recalls data carries no DIN and no company name, so notices are matched on wording alone — and 1,437 of the 2,306 drug notices in the feed could not be matched to any product at all. Check Health Canada’s own search before concluding anything.
Search Health Canada recalls for Jamp Lisdexamfetamine →
How RxMonitor matches recalls, and how often it fails
Source: Health Canada — Recalls and Safety Alerts. Data current as of 2026-08-12. Matched on product name, not on DIN — the feed carries none.